These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? Amsden GW J Antimicrob Chemother; 2005 Jan; 55(1):10-21. PubMed ID: 15590715 [TBL] [Abstract][Full Text] [Related]
3. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. Kinlay S J Am Coll Cardiol; 2007 May; 49(20):2003-9. PubMed ID: 17512355 [TBL] [Abstract][Full Text] [Related]
4. Recent developments in anti-inflammatory natural products. Gautam R; Jachak SM Med Res Rev; 2009 Sep; 29(5):767-820. PubMed ID: 19378317 [TBL] [Abstract][Full Text] [Related]
5. Atorvastatin affects C-reactive protein levels in patients with coronary artery disease. Karaca I; Ilkay E; Akbulut M; Yavuzkir M; Pekdemir M; Akbulut H; Arslan N Curr Med Res Opin; 2003; 19(3):187-91. PubMed ID: 12803732 [TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory activity of macrolide antibiotics. Ianaro A; Ialenti A; Maffia P; Sautebin L; Rombolà L; Carnuccio R; Iuvone T; D'Acquisto F; Di Rosa M J Pharmacol Exp Ther; 2000 Jan; 292(1):156-63. PubMed ID: 10604943 [TBL] [Abstract][Full Text] [Related]
7. Effect of macrolide antibiotics on nitric oxide synthase and xanthine oxidase activities, and malondialdehyde level in erythrocyte of the guinea pigs with experimental otitis media with effusion. Aktan B; Taysi S; Gümüştekin K; Uçüncü H; Memişoğullari R; Save K; Bakan N Pol J Pharmacol; 2003; 55(6):1105-10. PubMed ID: 14730107 [TBL] [Abstract][Full Text] [Related]
8. The macrolide immunosuppressants in dermatology: mechanisms of action. Marsland AM; Griffiths CE Eur J Dermatol; 2002; 12(6):618-22. PubMed ID: 12459545 [TBL] [Abstract][Full Text] [Related]
9. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691 [TBL] [Abstract][Full Text] [Related]
12. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study. Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245 [TBL] [Abstract][Full Text] [Related]
13. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels. Keleş T; Akar Bayram N; Kayhan T; Canbay A; Sahin D; Durmaz T; Ozdemir O; Aydoğdu S; Diker E Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535 [TBL] [Abstract][Full Text] [Related]
14. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation. Coimbra M; Banciu M; Fens MH; de Smet L; Cabaj M; Metselaar JM; Storm G; Schiffelers RM J Control Release; 2010 Dec; 148(3):303-10. PubMed ID: 20869410 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. Patrick L; Uzick M Altern Med Rev; 2001 Jun; 6(3):248-71. PubMed ID: 11410071 [TBL] [Abstract][Full Text] [Related]
16. Utilizing the power of microbial genetics to bridge the gap between the promise and the application of marine natural products. Fortman JL; Sherman DH Chembiochem; 2005 Jun; 6(6):960-78. PubMed ID: 15880675 [TBL] [Abstract][Full Text] [Related]
17. Pharmaceutically active secondary metabolites of microorganisms. Demain AL Appl Microbiol Biotechnol; 1999 Oct; 52(4):455-63. PubMed ID: 10570792 [TBL] [Abstract][Full Text] [Related]
18. Effect of atorvastatin and pravastatin on serum C-reactive protein. Kent SM; Flaherty PJ; Coyle LC; Markwood TT; Taylor AJ Am Heart J; 2003 Feb; 145(2):e8. PubMed ID: 12595863 [TBL] [Abstract][Full Text] [Related]
19. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Dornbrook-Lavender KA; Joy MS; Denu-Ciocca CJ; Chin H; Hogan SL; Pieper JA Pharmacotherapy; 2005 Mar; 25(3):335-44. PubMed ID: 15843280 [TBL] [Abstract][Full Text] [Related]
20. An update on bioactive plant lignans. Saleem M; Kim HJ; Ali MS; Lee YS Nat Prod Rep; 2005 Dec; 22(6):696-716. PubMed ID: 16311631 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]